NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash flow for capital expenditures refers to the cash generated minus spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.
Novo Nordisk A/S's cash flow for capital expenditures for the three months ended in Mar. 2015 was $-116 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2015 was $-724 Mil.
Novo Nordisk A/S Cash Flow for Capital Expenditures for the trailing twelve months (TTM) ended in Mar. 2015 was -162.045897814 (Jun. 2014 ) + -187.336599893 (Sep. 2014 ) + -258.984938112 (Dec. 2014 ) + -115.584302579 (Mar. 2015 ) = $-724 Mil.
Novo Nordisk A/S Annual Data
Novo Nordisk A/S Quarterly Data